Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma-Reference-Cited by-同舟云学术

Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma

Published:2014-07-02 Issue:6 Volume:93 Page:469-475
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

De la Cruz Vicente Fátima¹,Carrillo-Cruz Estrella¹,Rodriguez Maria Sole¹,Marín Niebla Ana²,Galiana Maria Luz Martino¹,Gonzalez Jose Falantes¹,Cuadrado Isabel Montero¹,Campos Jose Gonzalez¹,Tocino Ildefonso Espigado¹,Rios-Herranz Eduardo³,Perez-Simón Jose Antonio¹

Affiliation:

1. Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain

2. Hospital Vall d'Hebron; Sevilla Spain

3. Hospital Universitario Virgen de Valme; Sevilla Spain

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12384/fullpdf

Reference18 articles.

1. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance;Cohen;Haematologica,2003

2. New treatment options have changed the survival of patients with follicular lymphoma;Fisher;J Clin Oncol,2005

3. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi;Federico;J Clin Oncol,2013

4. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial;Rummel;Lancet,2013

5. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma;Forstpointner;Blood,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis;Annals of Hematology;2022-08-27

2. Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma;British Journal of Haematology;2019-02-28

3. Cyclophosphamide/fludarabine/rituximab;Reactions Weekly;2017-09

4. Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial;Annals of Hematology;2017-01-18

5. Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan;European Journal of Haematology;2016-05-30